The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
May 17th 2025
Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Exercise May Benefit Chemotherapy-Induced Peripheral Neuropathy in Patients With Ovarian Cancer
December 23rd 2024Exercise interventions may help manage chemotherapy-induced peripheral neuropathy (CIPN) in patients with ovarian cancer through improved physical activity and muscle function, but evidence remains limited.
Read More
Top 5 Most-Read IPF Content of 2024
December 23rd 2024The top 5 idiopathic pulmonary fibrosis (IPF) articles of 2024 explored topics like the effect of oxygen therapy on health care costs and mortality; delayed diagnoses leading to worse outcomes; new drug trials; the impact of diabetes on pulmonary health; and the growing body of research on macrophages and pulmonary fibrosis.
Read More
Early Intervention and Personalized Frontline Therapies in Multiple Myeloma
December 23rd 2024A panelist discusses how clinicians are navigating the evolving landscape of multiple myeloma treatment, from considering early intervention in high-risk smoldering cases to personalizing initial therapy choices between triplet and quadruplet regimens.
Watch
Clinical Value of Biosimilars and the Role of Interchangeability
December 21st 2024A panelist discusses how biosimilar adoption faces multiple barriers despite proven cost benefits, exploring strategies for improving uptake, best practices for interchangeability, experiences with adalimumab switching, and future optimization opportunities in healthcare systems.
Watch
Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa
December 20th 2024Panelist discusses how hidradenitis suppurativa’s early detection is challenging due to misdiagnosis, patient stigma, and limited awareness. Improved physician education, proactive screening, and strategic use of claims data can help identify undiagnosed cases earlier, enabling more timely intervention and management.
Watch
Dr Yehuda Handelsman on How DCRM 2.0 Guidelines Refine CRM Disease Management
December 20th 2024In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.
Read More
Background and Causes of Iron Deficiency Anemia
Panelists discuss how chronic kidney disease leads to iron deficiency anemia through a complex interplay of impaired iron absorption, increased hepcidin production driven by inflammatory cytokines, and reduced erythropoietin synthesis, resulting in both functional and absolute iron deficiency alongside diminished red blood cell production.
Watch
CGM: Redefining Type 2 Diabetes Management
December 19th 2024A panelist discusses how continuous glucose monitoring (CGM) technology can help overcome therapeutic inertia and key barriers to glycemic control in type 2 diabetes (T2D) patients by providing real-time data that enables earlier interventions, supports treatment optimization, and helps managed care organizations justify broader CGM adoption for newly diagnosed patients.
Watch
Infection Rate More Than Doubles in CLL/SLL Accompanied by Secondary Immunodeficiency Disease
December 19th 2024Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Read More
Further Refining the Myasthenia Gravis Continuum
December 19th 2024Finding similar frequencies of positive acetylcholine receptor antibodies in patients with ocular and generalized myasthenia gravis (MG), a Danish research team posits that ocular disease is most likely a more moderate form of generalized MG—not a fully separate condition.
Read More
Luspatercept Promising Against Anemia in MDS
December 18th 2024Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.
Read More
Iron Deficiency and Cardiovascular Interventions
December 18th 2024A panelist discusses how the multicenter ferric carboxymaltose trial employed a prospective design to evaluate iron supplementation's impact on heart failure outcomes, strategically selecting hospitalization reduction as the primary end point due to its clinical relevance and statistical power considerations.
Watch
Researchers Characterize Defining Feature of Pediatric AML Subtype
December 17th 2024Recently recognized by the World Health Organization, acute myeloid leukemia (AML) with t(7;12)(q36;p13) has previously been associated with MNX1 and ETV6 signaling, although MNX1::ETV6 fusion transcripts have only been confirmed in approximately half of cases.
Read More
Management of Recurrent C Difficile Infections in the Future
December 17th 2024Paul Feuerstadt, MD, FACG, AGAF, discusses how the management of recurrent Clostridioides difficile infections is evolving toward more targeted approaches, including microbiome-based therapies like fecal microbiota transplantation, newer antibiotics such as fidaxomicin, and emerging preventive strategies focusing on microbiome restoration and preservation.
Watch
Patient-Reported Outcomes Drive Effective MPN Treatment
December 16th 2024Demonstrating improvements in patient quality of life using patient-reported outcomes are important for treatments for myeloproliferative neoplasms (MPNs), said Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center.
Watch